Abstracts tagged "Behcet’s syndrome"

Abstract Number: 1806 • 2018 ACR/ARHP Annual Meeting
Spinal Cord Involvement in Behcet’s Disease- Experience of a Vasculitis Centre at Silk Road
Ertugrul Cagri Bolek, Alper Sari, Levent Kilic, Ali Akdogan, Meryem Asli Tuncer and Omer Karadag, Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey
Background/Purpose: Spinal cord involvement may occur in the course Behcet's Disease (BD). It may present with distinct manifestations such as sphincter and/or sexual dysfunction. We…
Abstract Number: 1773 • 2018 ACR/ARHP Annual Meeting
Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis Due to Behçet’s Disease. National Multicenter Study of 177 Cases
Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Vanesa Calvo-Río², Rosalía Demetrio-Pablo³, Emma Beltrán⁴, Marina Mesquida⁵, Alfredo Adan⁵, Juan Sánchez Bursón Sr.⁶, M. Victoria Hernández⁷, Marisa Hernández⁸, Elia Valls-Pascual⁹, L. Martinez-Costa⁹, Agusti Sellas-Fernandez¹⁰, Miguel Cordero-Coma¹¹, Manuel Díaz-Llopis¹², Roberto Gallego¹², Jose L. García Serrano¹³, Norberto Ortego Centeno¹⁴, Angel Garcia-Aparicio¹⁵, Olga Maiz-Alonso¹⁶, Ana Blanco¹⁷, Cruz Fernandez-Espartero¹⁸, Vega Jovaní¹⁹, Diana Peiteado²⁰, Elena Aurrecoechea²¹, Amalia Sanchez-Andrade²², Enrique Minguez²³, Carmen Carrasco-Cubero²⁴, Alejandro Olivé-Marqués²⁵, Esteban Rubio-Romero²⁶, Francisco J. Toyos Sáenz de Miera²⁷, David Diaz-Valle²⁸, Joan Miquel Nolla²⁹, Marcelino Revenga Martínez³⁰, Santos Castañeda³¹, Jose M Herreras³², Alejandro Fonollosa³³, Ignacio Torre-Salaberri³⁴, Esperanza Pato Cour³⁵, Juan Cruz³⁶, Carlos Férnandez Cid³⁷, Miriam García-Arias³⁸, Miguel Angel Caracuel-Ruiz³⁹, Carlos Alberto Montilla-Morales⁴⁰, Antonio Atanes⁴¹, Félix Francisco⁴², Santos Insua⁴³, Senen González-Suárez⁴⁴, Fernando Gamero⁴⁵, Luis Francisco Linares⁴⁶, Fredeswinda I. Romero-Bueno⁴⁷, Raquel Almodóvar González⁴⁸, Julio Vázquez⁴⁹, A. Javier García-González⁵⁰, Oscar Ruiz Moreno⁵¹, Fernando Jiménez-Zorzo⁵¹, Javier Manero⁵¹, Santiago Muñoz Fernandez⁵², Fred Antón Pages⁵³, Myriam Gandía⁵⁴, Francisco Javier López Longo⁵⁵, Enrique Raya Álvarez⁵⁶, Paz Rodríguez-Cundín⁵⁷, Diana Prieto Peña², Monica Calderón Goercke², Enar Pons¹, José Luis Hernández³, Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, ⁵Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁶Rheumatology, Hospital de Valme. Sevilla. Spain, Sevilla, Spain, ⁷Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁸Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁹Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ¹⁰Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ¹¹Ophthalmology, Hospital de León. Spain, León, Spain, ¹²Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ¹³Ophthalmology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ¹⁴Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ¹⁵Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, ¹⁶Hospital Universitario Donostia. San Sebastian. Spain, Donostia, Spain, ¹⁷Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, ¹⁸Rheumatology, Hospital de Móstoles. Madrid. Spain, Madrid, Spain, ¹⁹Rheumatology, Hospital General Universitario de Alicante. Spain, Alicante, Spain, ²⁰Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ²¹Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, ²²Rheumatology, Hospital Lucus Augusti. Lugo. Spain, Lugo, Spain, ²³Ophthalmology, Hospital Clínico de Zaragoza. Spain, Zaragoza, Spain, ²⁴Hospital de Mérida. Spain, Mérida, Spain, ²⁵Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, ²⁷Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ²⁸Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, ²⁹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³⁰Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, ³¹Rheumatology, Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, ³²Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, ³³Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, ³⁴Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ³⁵Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ³⁶Rheumatology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, ³⁷Ophthalmology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, ³⁸Hospital Universitario de la Princesa. Madrid. Spain, Madrid, Spain, ³⁹Rheumatology service, Hospital Universitario Reina Sofía. Córdoba. Spain, Córdoba, Spain, ⁴⁰Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ⁴¹Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, ⁴²Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, ⁴³Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, ⁴⁴Rheumatology, Hospital de Cabueñes. Gijón. Spain, Gijón, Spain, ⁴⁵Rheumatology, Hospital San Pedro Alcántara. Cáceres. Spain, Cáceres, Spain, ⁴⁶Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ⁴⁷Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, ⁴⁸Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, ⁴⁹Rheumatology, Hospital de Ferrol. La Coruña. Spain, La Coruña, Spain, ⁵⁰Rheumatology, Instituto de Investigación Hospital 12 de octubre. Madrid. Spain, Madrid, Spain, ⁵¹Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ⁵²Hospital Universitario Infanta Sofía. Madrid. Spain, San Sebastián de los Reyes (Madrid), Spain, ⁵³Rheumatology, Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, ⁵⁴Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, ⁵⁵Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵⁶Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁵⁷Preventive Medicine, Preventive Medicine. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain., Santander, Spain
Background/Purpose: Uveitis is one of the major causes of disability of Behçet's disease (BD). According to the “Expert panel recommendations” (Ophthalmology. 2014; 121:785-96), anti-TNF therapy…
Abstract Number: 1807 • 2018 ACR/ARHP Annual Meeting
Clinical Features and Disease Course of Neurologic Involvement in Behcet’s Disease
Ertugrul Cagri Bolek, Alper Sari, Berkan Armagan, Abdulsamet Erden, Levent Kilic, Umut Kalyoncu, Meryem Asli Tuncer, Sedat Kiraz and Omer Karadag, Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey
Background/Purpose: Neurological involvement (NBD) is a rare complication of BD. Although NBD is not common in the course of BD, it is related with significant…
Abstract Number: 1778 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical and Angiographic Features of Arterial Involvement in Takayasu’s Arteritis and Behcet’s Disease
Su Jin Choi¹, Doo-Ho Lim², Ji Seon Oh¹, Seokchan Hong¹, Yong-Gil Kim¹, Chang Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)
Background/Purpose: Systemic vasculitis is one of the major manifestations of Behcet’s disease (BD). Takayasu’s arteritis (TA) is a chronic vasculitis that primarily affects the aorta…
Abstract Number: 1809 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Older Age-Onset Behçet Syndrome Patients
Gul Guzelant¹, Yilmaz Ozyazgan², Cem Mat³, Vedat Hamuryudan¹, Hasan Yazici¹ and Emire Seyahi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey
Background/Purpose: The usual onset of Behçet syndrome (BS) is in the 3. decade. Older age-onset defined as fulfilling the International Study Group (ISG) criteria after…
Abstract Number: 1789 • 2018 ACR/ARHP Annual Meeting
Mucocutaneous Activity Index As a Patient-Reported Outcome Measure in Behcet’s Disease: A Multi-Center Study from Turkey
Haner Direskeneli, Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Organ-specific patient-reported outcome (PRO) measures may help management decisions of Behcet’s disease (BD). The aim of this prospective study was to evaluate the factors…
Abstract Number: 1810 • 2018 ACR/ARHP Annual Meeting
Initial Visit Symptoms in Probable Behçet’s Predictive of ISG Criteria Behçet’s: Data from New York and Amsterdam Cohorts
Floor Kerstens¹, Christopher J. Swearingen², Franktien Turkstra¹ and Yusuf Yazici³, ¹Amsterdam Rheumatology & Immunology Centre - Reade, Amsterdam, Netherlands, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Behçet’s syndrome (BS) is formally diagnosed using the International Study Group (ISG) criteria, where recurrent oral ulceration and any two other symptoms (recurrent genital…
Abstract Number: 1790 • 2018 ACR/ARHP Annual Meeting
An Unmet Need for Oral Ulcer Activity in Patients with Behcet’s Disease: A Multi-National Study
Gonca Mumcu¹, Adebowale Adesanya², Aysun Aksoy³, Joice Moraes Faria M Belem⁴, Natalia Borges Cardin⁴, Fatma Alibaz-Oner⁵, Tulin Ergun⁶, Nevsun Inanc⁷, Alexandre W.S. Souza⁸, Wafa Madanat⁹, Farida Fortune¹⁰ and Haner Direskeneli⁷, ¹Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ²Barts and The London, School of Medicine and Dentistry, Institute of Dentistry, Clinical and Diagnostic Oral Sciences, London, UK, London, United Kingdom, ³Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ⁴Rheumatology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ⁵Şerifali mahallesi İbrahim Hakkı sokak. Lavella 4 sitesi. B blok, D:22 Umraniye, Şerifali mahallesi İbrahim Hakkı sokak. Lavella 4 sitesi. B blok, D:22 Umraniye, Istanbul, Turkey, ⁶Department of Dermatology, Faculty of Medicine, Marmara University, Istanbul, Turkey, ⁷Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁸Rheumatology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁹Jordan’s Friends of Behcet’s disease Patients Society, Medical department, Amman, Jordan, Amman, Jordan, ¹⁰Dental Institute, Barts and The London NHS Trust, London, United Kingdom
Background/Purpose: Efficacy of current management approaches for oral ulcer treatment in routine clinical practice is insufficiently explored in Behcet’s disease (BD) patients. The aim of…
Abstract Number: 1811 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Interferon α2a As an Add-on Treatment for Refractory Behcet’s Uveitis
Jing Shi¹, Chan Zhao², Jiaxin Zhou³, JinJing Liu¹, Fei Gao², Xiaofeng Zeng⁴, Meifen Zhang² and Wenjie Zheng¹, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Department of Ophthalmology, Peking Union Medical College Hospital, Beijing, China, ³Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ⁴Rheumatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Uveitis is one of the leading causes of morbidity in Behcet’s patients which may result in irreversible vision loss. Evidence is accumulating that interferon…
Abstract Number: 1791 • 2018 ACR/ARHP Annual Meeting
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics
Gulen Hatemi¹, Alfred Mahr², Mitsuhiro Takeno³, Do-Young Kim⁴, Melike Melikoglu¹, Sue Cheng⁵, Shannon McCue⁵, Maria Paris⁵, Mindy Chen⁵ and Yusuf Yazici⁶, ¹Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ²Hospital Saint-Louis, University Paris Diderot, Paris, France, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Yonsei University College of Medicine and Severance Hospital, Seoul, Korea, Republic of (South), ⁵Celgene Corporation, Summit, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU) that can be disabling and negatively affect quality of life.…
Abstract Number: 1812 • 2018 ACR/ARHP Annual Meeting
Characterization and Prevalence of Morbus Behçet in Switzerland
Sabine Adler¹, Rahel Villiger², Lukas Buetikofer³ and Peter M. Villiger⁴, ¹Department of Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²Rheumatology, Immunology and Allergology, University Hospital Bern, Switzerland, Bern, Switzerland, ³Clinical Trials Unit, University of Bern, Bern, Switzerland, ⁴Rheumatology and Clin Immunol, Bern, Switzerland
Background/Purpose: To evaluate the clinical presentation of patients with Morbus Behçet (MB) in a cohort from Switzerland and to calculate the prevalence of MB in…
Abstract Number: 1794 • 2018 ACR/ARHP Annual Meeting
Venous Vessel Wall Thickness in Lower Extremity Is Increased in Male Behcet’s Disease Patients
Fatma Alibaz-Oner¹, Rabia Ergelen², Aydan Mutiş³, Zeynep Erturk¹, Ruslan Asadov⁴, Tulin Ergun⁵ and Haner Direskeneli⁶, ¹Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Marmara University School of Medicine, Radiology, ISTANBUL, Turkey, ³Marmara University, School of Medicine, Rheumatology, ISTANBUL, Turkey, ⁴Marmara University School of Medicine, Radiology, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, ⁶Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Vascular involvement is seen in up to 40% of the patients with Behcet's Disease (BD), especially in young males and is one of the…
Abstract Number: 1813 • 2018 ACR/ARHP Annual Meeting
Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease
Muhammed Aydin¹, Bahar Artim-Esen¹, Murat Inanc², Lale Ocal¹ and Ahmet Gül¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey
Background/Purpose: Behçet disease (BD) is a multisystem inflammatory disorder characterized by recurrent manifestations in mucocutaneous tissues, eyes, joints, blood vessels, intestines and brain. Since there…
Abstract Number: 1795 • 2018 ACR/ARHP Annual Meeting
New Major Organ Involvement Is Lower in Young Male Behçet’s Patients Compared to Retrospective Series: Five-Year Results of a Prospective Cohort
Fatma Alibaz-Oner¹, Belgin Aldag², Emrah Karatay³, Gonca Mumcu⁴, Tulin Ergun⁵ and Haner Direskeneli⁶, ¹Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ³Radiology, Marmara University, School of Medicine, Istanbul, Turkey, ⁴Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, ⁶Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Major organ involvement such as vascular or ocular disease, especially in young males, is one of the main causes of mortality and morbidity in…
Abstract Number: 1814 • 2018 ACR/ARHP Annual Meeting
Interferon-Alpha for the Management of Lower Extremity Deep Vein Thrombosis in Behcet’s Syndrome: A Case Series
Yesim Ozguler¹, Gulen Hatemi², Firat Cetinkaya³, Koray Tascilar⁴, Serdal Ugurlu¹, Emire Seyahi¹, Hasan Yazici¹ and Melike Melikoglu¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey, ⁴Numune Research and Teaching Hospital, Ankara, Turkey
Background/Purpose: Lower extremity deep vein thrombosis (LEDVT) is a disabling complication of Behcet’s syndrome (BS). Relapses are frequent and cause permanent disability due to post-thrombotic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].